A Phase III, Multicenter, Open-label Randomized Trial Comparing the Efficacy of GA101 (RO5072759) in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival, assessed by the investigator according to a modified version of the Revised Response Criteria for Malignant Lymphoma
up to approximately 78 months
No
Clinical Trials
Study Director
Hoffmann-La Roche
United States: Food and Drug Administration
BO21005
NCT01287741
July 2011
November 2016
Name | Location |
---|---|
Hinsdale, Illinois 60521 | |
Alexandria, Minnesota 56308 | |
Albany, Georgia 31701 | |
Birmingham, Alabama 35294 | |
Phoenix, Arizona 85012 | |
Fountain Valley, California 92708 | |
Albany, New York 12208 | |
Cleveland, Ohio 44195 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Seattle, Washington 98195 | |
McLean, Virginia 22101 | |
Scarborough, Maine 04074 | |
Denver, Colorado | |
Charlotte, North Carolina | |
Eugene, Oregon | |
Charleston, South Carolina |